Andrographolide Emerges as Malaria Drug Candidate

A computational study identifies a plant compound that may inhibit a parasite enzyme linked to malaria drug resistance.

Updated on Nov. 11, 2026 in Botany

Isometric editorial illustration of slender green herb stems beside a flask of pale amber liquid on a white bench, evoking a plant-derived malaria drug candidate.
Researchers identified andrographolide, a plant compound from Andrographis paniculata, as a possible inhibitor of a malaria parasite enzyme linked to drug resistance. AI Illustration. Upload story photo >

Researchers identified andrographolide, a compound from the herb Andrographis paniculata, as a putative inhibitor of PF11_0189, an essential enzyme of the malaria parasite Plasmodium falciparum, based on in silico docking and simulation. The findings are computational and have not yet been confirmed in laboratory or clinical testing.

Why it matters

Malaria caused by P. falciparum claims more than 600,000 lives each year, and partial artemisinin resistance has spread across South and Southeast Asia. Antimalarials with genuinely new mechanisms of action are therefore a global priority.

Andrographolide scored -8.4 kcal/mol in docking against PF11_0189, outscoring chloroquine at -6.9 kcal/mol, and showed a binding free energy of -42.3 kJ/mol. Triplicate 100-ns simulations kept backbone RMSD below 2.5 Å, though no laboratory validation has yet been reported.

The players

Andrographis paniculata

A medicinal herb documented as the most consistently used antimalarial plant across twelve tribal communities in Northeast India.

Plasmodium falciparum

The protozoan parasite responsible for the most lethal form of human malaria, which causes more than 600,000 deaths annually.

The details

The team docked ten phytochemicals from Andrographis paniculata against PF11_0189, an M16 insulinase-family metallopeptidase with no significant human homolog, and benchmarked the method against property-matched decoys. Andrographolide ranked as the top hit, had zero Lipinski violations, and remained stable in triplicate molecular dynamics runs.

Timeline

  1. 2026-11-11

    Study published early as accepted peer-reviewed research.

Deeper Dive

The search for new antimalarials is driven by partial artemisinin resistance spreading across South and Southeast Asia, which has made drugs with novel targets such as PF11_0189 a priority. Whether andrographolide can clear the experimental validation steps ahead will determine if it offers a real alternative to current treatments.

If validated, andrographolide could eventually inform new malaria treatments, but it remains a computational lead. Readers should not expect any change to malaria treatment or access based on this study alone.

The takeaway

A computational screen has nominated andrographolide as a candidate worth testing against a malaria drug target, but laboratory confirmation is still required before any therapeutic conclusion can be drawn.

Further reading

For related plant-based research, explore the Botany section.

Source note: This article includes information reported by Nature.